The US Food and Drug Administration (FDA) released a draft guidance on April 3 providing recommendations to sponsors and testing sites on data integrity for bioavailability and bioequivalence (BA/BE) ...
In an effort to enable faster commencement of Bioavailability/Bioequivalence (BA/BE) studies, particularly for the generic pharmaceutical industry in certain low-risk ...
Indian pharmaceutical companies are supporting the recent US FDA guidance on safety reporting requirements for Bioavailability (BA) and Bioequivalence (BE) studies. The new guidelines are seen as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results